British drug giant AstraZeneca (AZN)
has recently been racing to fix the holes in its pipeline created by
several high-profile clinical failures. The question for investors is
whether the company is at risk of pulling a Wile E. Coyote and running
right off the edge of the cliff. Although AstraZeneca has more work to
do to fix the near-term outlook, long-term investors may have a brighter
future now than just a few months ago.
Click here to continue:
AstraZeneca Sprinting To Fix Itself
No comments:
Post a Comment